La Jolla Pharmaceutical Co. said it is planning a registered offering of $100 million of its common shares.
The underwriter has a 30-day option to buy up to $15 million of the company's common shares.
Cowen is acting as sole book-running manager for the offering.
San Diego-based La Jolla plans to use proceeds from the offering for general corporate purposes, including the continued commercialization of blood pressure drug Giapreza as well as funding its ongoing and future clinical trials of LJPC-401, the company's proprietary formulation of a synthetic hormone.
